FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
Verified: 10 outlets in 7 countries have reported this story since Nov 9, 2 of them from the United States.
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent blindness. On Monday, the FDA announced that it is requiring all GLP-1 medications – including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, as well as Sanofi’s Soliqua – to include information about the potential risk of nonarteritic anterior ischemic optic neuropathy…
How sure are we
Two or more outlets reported this story and its reliability score reached 65%, so WorldPulse marks it verified. That means more than one outlet says so, not that it is proven true.
Who reported it
2 outlets from the United States, where the story is: Ars Technica, STAT News · how we count
- Nov 9, 4:19 PM UTCFirst reportSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionstatnews.com ↗
- Nov 9, 4:47 PM UTC+28 minFDA requires vision-loss warning on Novo Nordisk and Eli Lilly GLP-1 drugsinvesting.com ↗
- Nov 9, 9:58 PM UTC+6 hFDA adds rare vision-loss warning to popular GLP-1 weight loss drugsjamaica-gleaner.com ↗
- Nov 10, 8:21 PM UTC+28 hMakers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindnessbbc.co.uk ↗
- Nov 10, 8:42 PM UTC+28 h· you’re reading thisFDA warns of rare eye condition causing blindness from GLP-1 weight loss medicationstheguardian.com ↗
- Nov 10, 8:44 PM UTC+28 hFDA warns of rare eye condition causing blindness from GLP-1 weight loss medicationstheguardian.com (again) ↗
- Nov 11, 9:19 AM UTC+41 hMakers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindnesskbc.co.ke ↗
[Claude] All three other reports cover the same FDA order requiring NAION warnings on GLP-1 drug labels and do not contradict Report 1's facts.
42m agoOnly 1 source — pending corroboration
13h agoSingle timestamp
13h agoAverage source trust: 50%; Source tiers represented: national
13h agoNo authoritative sources yet — awaiting wire/institutional coverage
13h agoFDA warns of rare eye condition causing blindness from GLP-1 weight loss medications The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent blindness. On Monday, the FDA announced that it is requiring all GLP-1 medications – including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, as well as Sanofi’s Soliqua – to include information about the potential risk of nonarteritic anterior ischemic optic neuropathy…
Score bands
What moves the score
Not in the score: AI checks and reader flags. Verified is separate: two or more independent outlets and a score of at least 65%.
Very high · How we score this